The use of fluoroquinolones in chronic otitis suppurativa
Tóm tắt
Từ khóa
Tài liệu tham khảo
Paparella MM. The pathology of middle ear inflammation. Acta ORL Belg 1985;39:155–60.
Marquet JF, aVan de Heyning PH. Cholesteatoma or Keratoma, a pathological approach. Belg Tijdschr Radiol 1980;63:251–8.
Van de Heyning PH, Pattyn SR, Valcke HD. Ciprofloxacin in oral treatment of ear infections. Pharm Weekbl [Sci] 1986;8:63–6.
Alcock SR. Acute otitis extema in divers working in the North Sea: a microbiological survey of seven divers. J Hyg Camb 1977;78:395–407.
Papastravos T, Giamarellou H, Varlejides S. Role of aerobic and anaerobic micro-organisms in chronic suppurative otitis media. Larynscope 1986;96:438–42.
Brook I. Otitis media in children: a prospective study of aerobic and anaerobic bacteriology. Larynscope 1979;89:992–7.
Bluestone CD. Otitis media in children: to treat or not to treat? N Engl J Med 1982;306:1399–1404.
Fairbanks DN. Topical therapeutics for otitis media; Otolaryngol Head Neck Surg 1981;89:381–5.
Harada T, Iwamori M, Wagai Y, Nomura Y. Ototoxicity of neomycin and its penetration through the round window membrane into the perilymph. Ann. Otol Rhinol Laryngol 1986;95:404–8.
Lerner AM, Reyes MP, Copela, Blair DC, Jamen W, Wright GE, Lorber RR. Randomised, controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin. Lancet 1983;1:1123–6.
Chin NX, Neu HC. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrob Agents Chemother 1984;25:319–26.
Van Caekenberghe DL, Pattijn SR.In vitro activity of ciprofloxacin compared with those of other fluorinated piperazinylsubstituted quinolone derivates. Antimicrob Agents Chemother 1984;25:518–21.
Ball P. Ciprofloxacin: an overview of adverse experiences. J Antimicrob Chemother 1986;18:187–93.
Krajewski MJ. The effectiveness of enoxacin in the treatment of chronic suppurative otitis media. International Symposium on New Quinolones, Geneva, 1986, July 17–19.
Höffken G, Lode HK, Prinzig C. Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob Agents Chemother, 1985;27:375–9.
Ullmann U, Giebel W, Dachhoff A, Koeppe P. Single and multiple dose pharmaco-kinetics of ciprofloxacin. Eur J Clin Microbiol 1986;5:193–6.
Giamarellou H, Galanakis N, Dendrinos C, Stefanou J, Daphnis E, Daikos GK. Evaluation of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections. Eur J Clin Microbiol 1986;5:232–5.
Ganz H. Gyrasehemmer in der Lokalbehandlung von mit Problemkeimen chronish infizierten Mittelollroperationshöhlen. HNO 1986;24:511–4.
Fedelspil P. Efficacy and safety of ciprofloxacin in ear, nose and throat infections. In Proceedings First Internat. Ciprofloxacin Workshop, Leverkusen, Excerpta Media, 1986: 399–401.
Van de Heyning PH, Valcke HD, Pattyn SR, Van Caeckenberghe DL, Jans DL, Chysky HW, Boerema JB. The use of ciprofloxacin in surgical and non surgical ear-note-throat infections. International Symposium on Quinolones. Geneva, 1986, July, 17–9.
Ganz H. Clinical efficacy of ciprofloxacin in Otorhinolaryngological infections. In Proceedings First International Ciprofloxacin Workshop, Leverkusen, 1986. Excerpta Medica, 1986;395–6.